INDIANAPOLIS

印第安纳波利斯

,

，

Sept. 11, 2026

2026年9月11日

/PRNewswire/ -- Eli Lilly and Company (NYSE:

/美通社/ -- 礼来公司（纽约证券交易所：

LLY

礼来公司

) today announced the successful completion of its acquisition of AtaiBeckley Inc. AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions, including BPL-003, its lead investigational program for treatment-resistant depression.

）今日宣布，已成功完成对AtaiBeckley Inc.的收购。AtaiBeckley是一家临床阶段的生物制药公司，致力于开发用于精神健康疾病的快速起效神经可塑性调节剂，包括其领先的研究项目BPL-003，用于治疗难治性抑郁症。

'Treatment-resistant depression persists even after multiple treatment attempts, leaving millions of people still searching for relief,' said Carole Ho, Lilly executive vice president and president, Lilly Neuroscience. 'AtaiBeckley's neuroplastogens have the potential to open a new paradigm of treatment, with rapid-acting therapeutics designed to move away from chronic dosing. It's the innovation this field needs, and we are committed to advancing them for patients who need more options.'.

“即使经过多次治疗尝试，难治性抑郁症仍然持续存在，使数百万人仍在寻求缓解，”礼来公司执行副总裁兼礼来神经科学总裁Carole Ho表示。“AtaiBeckley的神经塑性药物有望开创一种新的治疗范式，其快速起效的治疗方案旨在摆脱长期给药模式。这正是该领域所需的创新，我们致力于推进这些疗法，为需要更多选择的患者提供帮助。”

The transaction was approved by AtaiBeckley shareholders at a special meeting held prior to closing.

该交易在交割前举行的特别会议上获得了AtaiBeckley股东的批准。

About Lilly

关于礼来

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases.

礼来是一家将科学转化为疗愈力量、致力于改善全球人民生活的制药公司。150年来，我们始终引领着改变生命的医学发现，如今我们的药物惠及全球数千万患者。依托生物技术、化学和基因医学的强大力量，我们的科学家正加紧推进新发现，以应对全球最重大的健康挑战：重新定义糖尿病护理；治疗肥胖并遏制其最具破坏性的长期影响；推进阿尔茨海默病的防治工作；为一些最使人衰弱的免疫系统疾病提供解决方案；并将最难治疗的癌症转化为可控制的疾病。

With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit .

在迈向更健康世界的每一步中，我们只受一个目标激励：让数百万人的生活变得更加美好。这包括开展反映世界多样性的创新临床试验，并致力于确保我们的药物可及且负担得起。欲了解更多信息，请访问。

Lilly.com

礼来官网

and

和

Lilly.com/news

礼来公司新闻

, or follow us on

，或在关注我们

Facebook

Facebook

,

，

Instagram

Instagram

, and

，以及

LinkedIn

领英

. F-LLY

F-LLY

Trademarks and Trade Names

商标与商号

All trademarks or trade names referred to in this press release are the property of Lilly, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto.

本新闻稿中提及的所有商标或商号均归礼来公司所有；若本新闻稿中提及属于其他公司的商标或商号，则其归各自所有者所有。仅为方便起见，本新闻稿中的商标和商号未附带®和™符号，但此类引用不应被解释为公司或在适用情况下其各自所有者不会根据适用法律最大限度地主张其相关权利的任何暗示。

We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies..

我们无意通过使用或展示其他公司的商标和商号来暗示我们与任何其它公司存在关联，或获得其认可或赞助。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性陈述的警示性声明

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of Lilly's acquisition of AtaiBeckley, Lilly's neuroscience platform and development plans, AtaiBeckley's clinical-stage pipeline of programs targeting mental health conditions, including its lead program, BPL-003, targeting treatment resistant depression, and plans for advancing AtaiBeckley's pipeline, and these statements reflect Lilly's current beliefs and expectations.

本新闻稿包含涉及礼来公司收购AtaiBeckley的益处、礼来的神经科学平台及开发计划、AtaiBeckley针对心理健康疾病（包括其针对难治性抑郁症的主要候选药物BPL-003）的临床阶段研发管线，以及推进AtaiBeckley研发管线的计划的前瞻性陈述（该术语定义见1995年《私人证券诉讼改革法案》），这些陈述反映了礼来公司当前的信念和预期。

However, as with any such undertaking, there are substantial risks and uncertainties in implementing the acquisition and in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that the acquisition will achieve the results discussed in this press release or that the acquisition will yield commercially successful products.

然而，与任何此类交易一样，在实施收购以及药物研发和商业化过程中存在重大风险和不确定性。除其他因素外，无法保证礼来公司能够实现收购的预期收益，无法保证收购能达到本新闻稿中讨论的结果，也无法保证收购将产生具有商业成功的产品。

For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this press release..

有关可能导致实际结果与礼来公司预期存在差异的上述及其他风险和不确定性的进一步讨论，请参阅礼来公司向美国证券交易委员会提交的10-K表和10-Q表文件。除法律要求外，礼来公司没有义务更新前瞻性陈述以反映本新闻稿发布日之后发生的事件。

Refer to:

请参考：

Megan Talon;

梅根·塔隆；

[email protected]

[email protected]

(Media)

（媒体）

Michael Czapar;

迈克尔·查帕尔；

[email protected]

[email protected]

(Investors)

（投资者）

SOURCE Eli Lilly and Company

来源：礼来公司

21

二十一

%

百分之

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示